Author(s): M. C. Damle, A. D. Chandan

Email(s): ,

DOI: 10.52711/0974-360X.2022.00927   

Address: M. C. Damle1*, A. D. Chandan2
1Head of Department, Pharmaceutical Quality Assurance, AISSMS College of Pharmacy, Pune.
2Department of Pharmaceutical Quality Assurance, AISSMS College of Pharmacy, Pune.
*Corresponding Author

Published In:   Volume - 15,      Issue - 12,     Year - 2022

The main objective of a research involved kinetic study of hydrolytic degradation of Rivaroxaban and validation of stability indicating HPTLC Method for estimation of rivaroxaban as per ICH guidelines.The chromatographic separation was carried on Merck TLC aluminium sheets of silica gel 60 F254 (10×10cm) with mobile phase of Acetonitrile: Ethyl acetate (3:7 v/v) with densitometric scanning at 249nm. Acceptable peak parameters were obtained at the retardation factor of about 0.75±0.02. The proposed method was validated according to ICH guidelines. The results were acceptable for linearity and range, accuracy, precision, robustness, detection limit and quantitation limit. During stress degradation study, it was observed that the rivaroxaban is more sensitive to hydrolytic conditions. Degradation product peak was well resolved when the sample exposed to alkali catalysed hydrolysis for 72 hrs. was spotted on TLC plate and studied by the developed method. Such a product peak was not observed at 48 hrs. exposure, though there was reduction in drug peak area. This prompted us to study degradation kinetics under alkaline hydrolytic conditions, and the results of the degradation kinetic study indicates that the reaction follows first order kinetics. Interestingly there was no product peak under acidic hydrolytic condition. Results of thermal, oxidative and photolytic degradation studies show reduction in drug peak area.The developed method describes simple, sensitive, and specific stability indicating HPTLC method for estimation of rivaroxaban. This optimised method can be considered as good alternative for routine analysis of the rivaroxaban stability.

Cite this article:
M. C. Damle, A. D. Chandan. Kinetic Study of Hydrolytic degradation of Rivaroxaban by HPTLC. Research Journal of Pharmacy and Technology2022; 15(12):5495-0. doi: 10.52711/0974-360X.2022.00927

M. C. Damle, A. D. Chandan. Kinetic Study of Hydrolytic degradation of Rivaroxaban by HPTLC. Research Journal of Pharmacy and Technology2022; 15(12):5495-0. doi: 10.52711/0974-360X.2022.00927   Available on:

1.    Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376-81.
2.    Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem.2005;48(19):5900-8. doi: 10.1021/jm050101d, PMID 16161994.
3.    Abdallah MA, Al-Ghobashy MA, Lotfy HM. Investigation of the profile and kinetics of degradation of Rivaroxaban using HPLC, TLC-densitometry and LC/MS/MS: application to pre- formulation studies. Bull Fac Pharm Cairo Univ.2015;53(1):53-61. doi: 10.1016/j.bfopcu.2015.01.002.
4.    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, BullerHR, Levi M. Reversal of Rivaroxaban and dabigatran by pro-thrombin complex concentrate a randomized, placebocontrolled, crossover study in healthy subjects.Circulation. 2011;124(14):1573-9. doi: 10.1161/Circulationaha.111.029017, PMID 21900088.
5.    Turpie AGG. New oral anticoagulants in atrial fibrillation.Eur Heart J. 2008;29(2):155-65.
6.    Dobesh PP, Fanikos J. Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. Is one of these not like the others?J Atr Fibrillation. 2016;9(2):1481. doi: 10.4022/jafib.1481, PMID 27909544.
7.    Available from: (Accessed on 19 august 2021)
8.    Walter ME. Development and validation of a stability-indicating RP-HPLC method for the determination of Rivaroxaban in pharmaceutical formulations. Lat American J Pharm. 2015; 34(8): 1503-10.
9.    Girase YN, Srinivasrao V, Soni D. Development and Validation of Stability Indicating RP-HPLC Method for Rivaroxaban and Its Impurities, Symbiosis online. J Biochem. 2018;4(1):1-6.
10.    Burla SVS, Peruri VV, Chandra BS. Application of stability indicating HPLC method with UV detector to the analysis of Rivaroxaban in bulk and tablet dosage form. Chem Sci Trans. 2014; 3(4):1546-54.
11.    Mandake GR, Patil IS, Patil OA, Nitalikar MM, Mohite SK. UV spectroscopy analysis and degradation study of Rivaroxaban. Asian J Res Pharm Sci. 2018; 8(2): 57-60. doi: 10.5958/2231-5659.2018.00012.7.
12.    Souri E, Mottaghi S, Zargarpoor M, Ahmadkhaniha R, Jalalizadeh H. Development of a stability-indicating HPLC method and a dissolution test for Rivaroxaban dosage forms. Acta Chromatographica. 2016; 28(3): 347-61. doi: 10.1556/1326.2016.28.3.05.
13.    Mustafa Ç, Tuba R, Engi K, Sacide A. RP-HPLC method development and validation for estimation of Rivaroxaban in pharmaceutical dosage forms, BJPS. Vol.49n(2, Apr/jun). p.34-8.
14.    Rajan N, Anver BK. A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in Rivaroxaban active pharmaceutical ingredient. J Pharm Res. 2014;8(11):1719-25.
15.    Wingert NR, dos Santos No, Nunes MA, Gomes P, Müller EI, Flores ÉM, Steppe M. Characterization of three main degradation products from novel oral anticoagulant Rivaroxaban under stress conditions by UPLC- Q- TOF-MS/MS. J Pharm Biomed Anal. 2016;123:10-5. doi: 10.1016/j.jpba.2016.01.053, PMID 26855380.
16.    PatilP, Wawdhane S, Chaudhari P. Identification, Separation and Characterization of Acidic and Alkali Degradation of Rivaroxaban under ICH Recommended stress Condition by HPTLC with MS/TOF, Taylor & Francis Group, TACL. 2017;7(5):706-23.
17.    Sethi PD. Quantitative analysis of pharmaceutical formulations. In: HPTLC – High performance thin layerchromatography. 1st ed. Mumbai: CBS Publishers and Distributors. Mumbai; 1996. p.3-5, 10, 18-20, 24, 27-8.
18.    StahlE.Thin layer chromatography A laboratory handbook. 2nd ed. India: Springer. India; 2016. p. 52-66.
19.    ICH.Q1A (R2) Stability testing of new drug substances and products. International Conference on Harmonization 2003; Geneva.
20.    ICH.Q2 (R1) Validation of Analytical Procedures. In: Proceedings of the International Conference on Harmonization 2005; Geneva.
21.    Nazira S, Bitar Y, Sarraj M. M.Development and validation of RP-HPLC method for simultaneous estimation of aspirin and Rivaroxaban in synthetic mixture. Res J Pharm Technol. 2020;13(11)(l):5459-65. doi: 10.5958/0974-360X.2020.00953.1.
22.    Arous B, Al-Mardini MA, Ghazal H, Al-Lahham F.Stability-indicating method for the determination of Rivaroxaban and its degradation products using LC-MS and TLC. Res J Pharm Technol. 2018; 11(1): 212-20. doi: 10.5958/0974-360X.2018.00040.9.
23.    Malik K. C.Karwa M, Jain G.K, Dutt R. Development and Validation of UPLC-MS/MS Method for the determination of Rivaroxaban in human plasma using liquid–liquid extraction. Res J Pharm Technol. 2021; 14(6): 3239-43. doi: 10.52711/0974-360X.2021.00563.
24.    Soudi AT, Hussein OG, Eman S. Elzanfaly, Hala E. Zaazaa, Mohamed Abdelkawy. Stability Indicating TLC–Densitometric Method for Determination of Alcaftadine in Presence of its Degradation Products and Dosage form Preservatives. Research J. Pharm. and Tech. 2020 13(11): 5171-5176. doi: 10.5958/0974-360X.2020.00904.X  
25.    Rawat S, Gupta A. Development of Novel HPTLC Method for Estimation of Qurcetine in Ocimum sanctum. Asian J. Pharm. Tech. 2011 Oct-Dec 1(4): 149-151.
26.    Bhusari VK, Dhaneshwar SR. Development and Validation of a Stability-Indicating HPTLC Method for the Estimation of Eszopiclone in Pharmaceutical Dosage Forms. Asian Journal of Research in Pharmaceutical Sciences. 2021 11(3): 219-3. doi: 10.52711/2231-5659.2021.00035
27.    Shelar KU, Rao JR, Dhale C. Stability indicating HPTLC method development and validation for the estimation of celecoxib in bulk drug and its Pharmaceutical formulation. Research J. Pharm. and Tech. 2020 13(8): 3661-3665. doi: 10.5958/0974-360X.2020.00647.2  
28.    Patil PH, Gurupadayya BM, Hamrapurkar PD. Stability Indicating HPTLC Determination of Tadalafil Hydrochloride in Bulk Drug and Pharmaceutical Formulations. Research J. Pharm. and Tech. 2020; 13(6): 2608-2614. doi: 10.5958/0974-360X.2020.00464.3  
29.    Sinha PK, Jeswani RM, Topgi KS, Damle MC. Stability Indicating RP-HPLC Method for Determination of Potassium Clavulanate in the presence of its Degradation Products. Research J. Pharm. and Tech. 2010 Jan. - Mar 3(1): 141-145.  
30.    Deshpande K, Ranaware P, Madgulkar AR, Damle MC. Development and Validation of Stability Indicating HPTLC Method for Determination of Repaglinide. Research J. Pharm. and Tech. 2013 Feb.  6(2): 158-161.
31.    Bramhankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics.2nded. Delhi. Vallah Prakashan:216-7.
32.    Badroon T, Sreeramulu J. Development and validation of stability indicating assay by HPLC method for estimation of Rivaroxaban, Journal of Bio-Pharma Research. Vol 8. Issue 5 pp.2582-6, 2019.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available